Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions

US8058264B2 · kind B2 · utility

Assignee

• ABBOTT PRODUCTS GMBH · DE

Inventors

• Michael Firnges · Barsinghausen, DE
• Peter-Colin Gregory · Hannover, DE
• Jochen Antel · Annaberg-Buchholz, DE
• Josephus Hubertus Maria Lange · Almere, NL
• Harald Waldeck · Hannover, DE

Key dates

• Filing date: Oct 25, 2005
• Grant date: Nov 15, 2011
• Expiry date: Aug 22, 2029

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/044
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described is a novel combination therapy for diabetes mellitus type I and/or for obesity and its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, by administering a combination of at least one KATP channel opener as a first active agent and at least one CB1 cannabinoid receptor antagonist as a second active agent. The invention is further directed to such novel combination therapy wherein a dually acting compound with combined KATP channel opening and CB1 antagonistic properties is used. The invention also relates to novel pharmaceutical compositions comprising KATP channel openers and CB1 antagonists and the use of said pharmaceutical compositions in the treatment, delayed progression, delayed onset of and/or inhibition of diabetes mellitus type 1, and the prophylaxis and treatment, of obesity as well as the prophylaxis, treatment, delayed onset and/or inhbition of its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, in mammals and humans. The invention is further directed to such novel pharmaceu…